Sarms GW501516

GW501516 (also known as GW-501,516, GW1516, GSK-516 and on the black market as Endurobol[1]) is a PPARδ receptor agonist that was invented in a collaboration between Ligand rmaceuticals and GlaxoSmithKc; in the 1990s, was entered into clinical development as a drug candidate for metabolic diseases and cardiovascular diseases, and was abandoned in 2007 because animal testing showed that the drug caused cancer to develop rapidly in several organs.[2]

In 2007 research was published showing that high doses of GW501516 given to mice dramatically improved their sical performance; the work was widely discussed in popular media, and led to a black market for the drug candidate and to its abuse by athletes as a doping agent. The World Anti-Doping Agency (WADA) developed a test for GW501516 and other related chemicals and added them to the prohibited list in 2009; it has issued additional warnings to athletes that GW501516 is not safe.